Regulators at the FDA raised questions about the effectiveness of Dendreon's Provenge for prostate cancer in advance of an expert committee meeting on the therapy Thursday. Dendreon is banking on studies that show that patients taking Provenge lived on average an extra four and a half months. But regulators highlighted the fact that the drug did not attain certain effectiveness targets, adding that some data did support use of the therapy.
- read the AP report on the committee meeting
Related Articles:
Dendreon to pursue Provenge approval. Report
Dendreon plans to raise $59M to market Provenge. Report
Dendreon's Provenge gets mixed grade in second Phase III. Report